Skip to content

Gastroparesis Registry 4

Gastroparesis Registry 4 (GpR4): Improving the Understanding of Gastroparesis and Functional Dyspepsia

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05846802
Acronym
GpR4
Enrollment
250
Registered
2023-05-06
Start date
2024-09-20
Completion date
2027-04-30
Last updated
2026-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Functional Disorder of Gastrointestinal Tract, Gastro-Intestinal Disorder, Gastroparesis, Gastroparesis Due to Diabetes Mellitus Type I, Gastroparesis Due to Diabetes Mellitus Type II, Gastroparesis Nondiabetic

Brief summary

The Gastroparesis Registry 4 (GpR4) is an observational study of patients with symptoms of gastroparesis (Gp) and functional dyspepsia (FD) with either delayed or normal gastric emptying. To better understand these disorders, this registry will capture demographic, clinical, physiological, questionnaire, and patient outcome data to characterize the patients and their clinical course. Participants will complete several questionnaires, complete a nutrient drink test and have a gastric emptying study.

Detailed description

This observational study of patients with symptoms of gastroparesis (Gp) and functional dyspepsia (FD) with either delayed or normal gastric emptying aims to assess the clinical, pathophysiological, and psychological similarities and differences between patients with Gp, FD. The primary outcome will be the measure of symptom severity of gastroparesis and functional dyspepsia using the change in total score from the Patient Assessment of Upper Gastrointestinal Disorders Symptoms (PAGI SYM) from baseline to 48 weeks.

Interventions

None listed

Sponsors

Johns Hopkins Bloomberg School of Public Health
Lead SponsorOTHER
Texas Tech University Health Sciences Center, El Paso
CollaboratorOTHER
Temple University
CollaboratorOTHER
University of Louisville
CollaboratorOTHER
Mayo Clinic
CollaboratorOTHER
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
CollaboratorNIH
Massachusetts General Hospital
CollaboratorOTHER
Wake Forest University
CollaboratorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

* Age at least 18 years at initial screening visit * Symptoms of Gp and/or FD of at least 12-weeks duration with varying degrees of nausea, vomiting, early satiety, postprandial fullness, abdominal pain, abdominal burning. Thus, patients can enter the GpR4 registry primarily with abdominal pain suggesting FD-Epigastric Pain Syndrome. * Successful completion of gastric emptying scintigraphy of solids using the 4-hour Egg Beaters® protocol (or equivalent generic liquid egg white meal) within the last 9 months * Negative upper endoscopy or upper radiographic GI series within 5 years of registration

Exclusion criteria

* Use of narcotic analgesics greater than three days per week * Presence of other conditions that could explain the patient's symptoms such as: * Pyloric or intestinal obstruction as evidenced by EGD, UGI, or Abdominal CT * Active inflammatory bowel disease * Known eosinophilic gastroenteritis or eosinophilic esophagitis * Primary neurological conditions that can cause nausea and vomiting such as increased intracranial pressure, space occupying or inflammatory/infectious lesions * Acute or chronic renal failure (serum creatinine \>3 mg/dL) and/or on hemodialysis or peritoneal dialysis * Acute liver failure or advanced liver disease (Child's B or C; a Child-Pugh-Turcotte (CPT) score of ≥7) * Pancreatic disorder if present on pancreatic imaging or pancreatic function testing * Prior gastric surgery including total or subtotal (near complete) gastric resection, esophagectomy, gastrojejunostomy, gastric bypass, gastric sleeve, pyloroplasty, pyloromyotomy, or any fundoplication (Nissen, Tor) * Any other condition, which in the opinion of the investigator, could explain the symptoms or interfere with study requirements * Females who are pregnant. A urine pregnancy test is routinely obtained on all females immediately prior to gastric emptying procedures. * Inability to comply with or complete the gastric emptying scintigraphy test (including allergy to eggs) * Inability to obtain informed consent

Design outcomes

Primary

MeasureTime frameDescription
Measure of symptom severity of gastroparesis and functional dyspepsia using the change in total score from the Patient Assessment of Upper Gastrointestinal Disorders Symptoms (PAGI SYM) from baseline to 48 weeks.48 weeksChange in PAGI-SYM total score from baseline to 48 weeks. The final PAGI-SYM contains 20 items grouped into 6 subscales covering: heartburn/regurgitation (7 items), nausea/vomiting (3 items), post-prandial fullness/early satiety (4 items), bloating (2 items), upper abdominal pain (2 items), and lower abdominal pain (2 items). A 6-point Likert response scale, ranging from 0 (none) to 5 (very severe), is used for rating the severity of each symptom item over a 2-week recall period. * Subscale scores vary from 0 to 5 * Total score varies from 0 to 5 * Lower score = better health

Secondary

MeasureTime frameDescription
Changes in gastric emptying, as measured by gastric emptying scintigraphy (GES) at baseline and 48 weeksBaseline, 48 weeksChanges in gastric emptying, as measured by gastric emptying scintigraphy (GES) at baseline and 48 weeks. Normal values for gastric emptying scintigraphy have been established in earlier studies using healthy volunteers. Gastric retention of 99mTc \> 60% at 2 hours and/or \> 10% at 4 hours is considered evidence of delayed gastric emptying of solids.

Countries

United States

Contacts

CONTACTLaura Miriel
lmiriel1@jhu.edu4435024165
CONTACTEmily Mitchell, MS, MBA
esharke5@jhu.edu
PRINCIPAL_INVESTIGATORJay Pasricha, MD

Mayo Clinic

PRINCIPAL_INVESTIGATORHenry Parkman, MD

Temple University

PRINCIPAL_INVESTIGATORDavid Shade, JD

Johns Hopkins Bloomberg School of Public Health

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 4, 2026